Increased expression of stromal ColX has previously been shown to correlate with worse survival outcomes in breast cancer cohorts with diverse tumor mutational burdens [13, 119], and COL10A1 has also been linked to negative prognosis in pancreatic cancer [93]. Here, COL10A1 is linked to breast cancer.